Akèy › Kansè tete negatif triple › Maryland › Baltimore
Etid klinik pou Kansè tete negatif triple nan Baltimore, MD
12 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan ak bò kote Baltimore (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Ap rekriteFaz 3
- MedStar Franklin Square Medical Center ( Site 0031), Baltimore
- MedStar Good Samaritan Hospital ( Site 0079), Baltimore
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Ap rekriteFaz 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Ap rekriteFaz 1
- United Theranostics, Glen Burnie · 9 mi lwen
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Ap rekriteFaz 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Ap rekriteFaz 3
- Sinai Hospital of Baltimore, Inc., Baltimore
- St. Agnes Hospital, Baltimore
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
- ak 1 plis
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Ap rekriteFaz 2
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- Local Institution - 1035, Baltimore
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Ap rekriteFaz 1
- United Theranostics, Glen Burnie · 9 mi lwen
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Ap rekriteFaz 1/2
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Ap rekriteFaz 2
- University of Maryland Medical Center (UMMC), Baltimore
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Ap rekriteFaz 1
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Etid Kansè tete negatif triple nan lòt vil
- Houston, TX42 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA27 etid
- Boston, MA26 etid
- San Antonio, TX23 etid
- St. Louis, MO21 etid
- Arlington, VA20 etid
- Atlanta, GA20 etid
- Dallas, TX18 etid
- Chicago, IL16 etid
- Columbus, OH16 etid
Lòt etid nan Baltimore
- Kansè Poumon ki pa ti selil60 etid
- Kansè nan tete47 etid
- Kansè pwostat43 etid
- Kansè poumon40 etid
- Kansè (tout kalite)37 etid
- Kansè pankreyas31 etid
- Kansè kolorektal31 etid
- Kansè Metastatik28 etid
- Obèsite26 etid
- Kansè vejik24 etid
- Ensifizyans kadyak24 etid
- Kansè ovè22 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.